Two new publications disclosing new drug-conjugate MES-1088 "C6" in comparison to MES-1007 "C3" in repairing critical bone defects.
These two preclinical research revealed that Mesentech drug candidates MES-1007 and MES-1088 (previously referred to as C3 and C6) resulted in significant osteoinduction on a critical bone defect. The critical defect was repaired with bone-grafting biomaterials such as Geistlich Bio-Oss® or a generic bone powder (monetite) that was fabricated in-house. These bone matrices were used either alone or drugged with either MES-1007 or MES-1088. The Journal of Periodontology discusses Geistlich Bio-Oss® performance while the Journal of Biomedical Materials discusses the performance of monetite. The addition of an osteoinductive vastly improves the performance of both of these compounds and raises questions on the utility of non-resorbable bone matrix.